Parainfluenza virus type 3 infectious disease

Summary

Parainfluenza virus type 3 infectious disease (MONDO:0042974) is a disease and 1 clinical trial. A subtype of respirovirus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	parainfluenza virus type 3 infectious disease
Mondo ID	MONDO:0042974
SNOMED CT	30270006
UMLS	C0276324
MedGen	547264
GARD	0004215
Is cancer (heuristic)	no

Also known as: human parainfluenza virus type 3 · human respirovirus 3 caused disease or disorder · human respirovirus 3 disease or disorder · human respirovirus 3 infectious disease · infection caused by human parainfluenza virus 3 · infection caused by parainfluenza virus 3 · infection due to human parainfluenza virus 3 · infection due to parainfluenza virus 3 · PIV3

Disease family

This is a subtype of respirovirus infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Paramyxoviridae infectious disease › respirovirus infectious disease › parainfluenza virus type 3 infectious disease

Related subtypes (1): parainfluenza virus type 1 infectious disease

Subtypes (1): fetal parainfluenza virus type 3 syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06546423	PHASE1	COMPLETED	Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age